Replies to post #130376 on Biotech Values

[oc631]

VRTX commits to test 12w Incivek+VX-222+ifn+ribavirin in phase-3

What's the earliest date this could be brought to market? Do you think this is efficient use of shareholder funds? VRTX also has two arms without interferon yet I doubt ribavirin alone will provide the resistance profile needed to prevent breakthrough.